
Erasca (ERAS) announced a clinical trial collaboration and supply agreement, or CTCSA, with Bristol Myers Squibb (BMY) to evaluate Erasca’s potentially best-in-class pan-RAS molecular glue, ERAS-0015, with navlimetostat, BMS’s investigational
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ERAS | Erasca | 13.89 | 11.03 | 385.66% |
| Name | Price | % Change | |
|---|---|---|---|
| $13.89 | +385.66% |

Erasca (ERAS) announced a clinical trial collaboration and supply agreement, or CTCSA, with Bristol Myers Squibb (BMY) to evaluate Erasca’s potentially best-in-class pan-RAS molecular glue, ERAS-0015, with navlimetostat, BMS’s investigational

Leerink initiated coverage of Erasca (ERAS) with an Outperform rating and $35 price target. Erasca’s ERAS-0015 has an elegantly enhance exposure profile, potentially enabling the efficacy without the same level

Leerink initiated coverage of Erasca (ERAS) with an Outperform rating and $35 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Erasca, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Laaman from Morgan Stanley maintained a Hold rating on the stock and has a $21.00

Pre-earnings options volume in Erasca (ERAS) Inc is 9.1x normal with calls leading puts 46:1. Implied volatility suggests the market is anticipating a move near 12.8%, or 0c, after results

Erasca, Inc. (ERAS) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Erasca, Inc. to post earnings of -$0.13 per share. Last quarter,

Tango Therapeutics (TNGX) and Erasca (ERAS) announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted pancreatic ductal

Erasca ( ($ERAS) ) just unveiled an update. On October 15, 2026, Erasca, Inc. announced a leadership realignment to better support the development and potential commercialization of its RAS-targeting oncology

JPMorgan holds a conference call with management on October 5 at 1:30 pm. Webcast Link Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

Erasca, Inc. ($ERAS) announced an update on their ongoing clinical study. The Phase 1/1b study An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor tests
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 17, 2026 | ||||
| buy | Initiated | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| hold | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Sep 1, 2026 | ||||
| buy | Reiterated | Aug 17, 2026 | ||||
| buy | Reiterated | Aug 12, 2026 | ||||
| buy | Assigned | Jul 14, 2026 | ||||
| buy | Reiterated | Apr 28, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 25, 2027TBA | $5.30B | $-0.15 | $0.00 | 0.23 | -15.31 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.